Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.55 |
| ▸ | GABRD | O14764 | 4/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.55 |
| ▸ | GABRE | P78334 | 4/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917429 | 0.83 | PARP1 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18840131 | 0.83 | SMN1; SMN2 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Potassium Ion SCHEMBL20565973 | 0.80 | KDM4E (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27970428 | 0.80 | MAPT (0.51) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL28641221 | 0.79 | HDAC1 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29942878 | 0.79 | KDM4E (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL21256547 | 0.79 | PLK1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1266209 | 0.79 | KDM4E (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL11296731 | 0.79 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14370837 | 0.79 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019451-A | Fungicidal compositions comprising fludioxonil | 先正达农作物保护股份公司 | 2024-05-10 | — | — | CN | claimed |
| CN-115209736-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2022-10-18 | — | — | CN | claimed |
| CN-115209735-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2022-10-18 | — | — | CN | claimed |
| EP-3162796-B1 | METHOD FOR PRODUCING 2-AMINO-6-METHYLNICOTINIC ACID | AGRO KANESHO CO LTD (JP) | 2021-06-09 | — | — | EP | claimed |
| CN-106458908-B | The manufacturing method of 2- amino -6- methylnicotinic acids | 阿格罗－金正株式会社 | 2018-11-06 | — | — | CN | claimed |
| US-9902697-B2 | Method for producing 2-amino-6-methylnicotinic acid | AGRO-KANESHO CO., LTD. (JP) | 2018-02-27 | — | — | US | claimed |
| US-9714223-B2 | — | — | 2017-07-25 | — | — | US | claimed |
| US-20170129858-A1 | METHOD FOR PRODUCING 2-AMINO-6-METHYLNICOTINIC ACID | AGRO-KANESHO CO., LTD. (JP) | 2017-05-11 | — | — | US | claimed |
| EP-3162796-A1 | METHOD FOR PRODUCING 2-AMINO-6-METHYLNICOTINIC ACID | Agro-Kanesho Co., Ltd. (JP) | 2017-05-03 | — | — | EP | claimed |
| CN-106458908-A | Method for producing 2-amino-6-methylnicotinic acid | 阿格罗－金正株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-119841817-B | Aromatic ester compound containing benzo five-membered ring, and preparation method and application thereof | 山东省联合农药工业有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250382288-A1 | 8-AZA QUINAZOLINES AS BRAIN-PENETRANT SOS1-INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
| US-3962264-A | AMMONIA, TETRA-ALKOXY-PROPANE, MALONONITRILE | PFIZER INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3950160-A | INHIBITING THE GROWTH OF WEEDS WITH 2-SUBSTITUTED PYRDIDOPYIMIDINES AND SALTS THEREOF | PFIZER INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382288-A1 | 8-AZA QUINAZOLINES AS BRAIN-PENETRANT SOS1-INHIBITORS | SOS1, SOS2, SOST | GABRP 3559/4885GABRD 3250/4885GABRA1 1692/4885 |
| US-20170129858-A1 | METHOD FOR PRODUCING 2-AMINO-6-METHYLNICOTINIC ACID | MAT2A, AADAT, AMPD2 | GABRP 2406/4885GABRD 2655/4885GABRA1 1473/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | GABRP 3529/4885GABRD 2461/4885GABRA1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.